Stocks To Buy Forum

Stocks to Buy based on the Best Stock Market Research

AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK

Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL

Axsome (AXSM)

Market-Cap: $83 Million
Cash: $50.6 Million

Shares Out: 23 Million

Anticipated Near-Term Clinical Milestones

Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

Clinical Trial Readouts:

-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

New Presentation

Major Shareholders

Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%

Views: 336

Reply to This

Stocks I'm Watching in 2017: TNA SHAK YINN UDOW SPXL SGY CLR and more...

Replies to This Discussion

maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .

Latest stock market analyst ratings:

Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.

Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.

here we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 .

5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .

Marketcap: $90 Million
Cash: $50 Million
Price: $3.95

New Presentation

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3

AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.

Need to break the MA(50) at $4.24 then $5+ coming

Fantastic News out today...

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation


Another Guy likes AXSM ...more and more people discover this stock and realize the mega potential here


Stocks to Buy 2017

Stocks to Buy 2017

Small Cap Bull 3x (TNA)
Shake Shack (SHAK)
Stocks to Watch - 2017
Penny Stocks - 2017

Twitter - Free Stock Alerts

© 2017   Created by Stocks To Buy.   Powered by

Badges  |  Report an Issue  |  Terms of Service